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MaOBJECTIVES The aim of this study was to: 1) provide tissue validation of quantitative T2 mapping to measure plaque
lipid content; and 2) investigate whether this technique could discern differences in plaque characteristics between
symptom-related and non–symptom-related carotid plaques.
BACKGROUND Noninvasive plaque lipid quantiﬁcation is appealing both for stratiﬁcation in treatment selection and as
a possible predictor of future plaque rupture. However, current cardiovascular magnetic resonance (CMR) methods are
insensitive, require a coalesced mass of lipid core, and rely on multicontrast acquisition with contrast media and extensive
post-processing.
METHODS Patients scheduled for carotid endarterectomy were recruited for 3-T carotid CMR before surgery. Lipid area
was derived from segmented T2 maps and compared directly to plaque lipid deﬁned by histology.
RESULTS Lipid area (%) on T2 mapping and histology showed excellent correlation, both by individual slices (R ¼ 0.85,
p < 0.001) and plaque average (R ¼ 0.83, p < 0.001). Lipid area (%) on T2 maps was signiﬁcantly higher in symptomatic
compared with asymptomatic plaques (31.5  3.7% vs. 15.8  3.1%; p ¼ 0.005) despite similar degrees of carotid
stenosis and only modest difference in plaque volume (128.0  6.0 mm3 symptomatic vs. 105.6  9.4 mm3 asymp-
tomatic; p ¼ 0.04). Receiver-operating characteristic analysis showed that T2 mapping has a good ability to discriminate
between symptomatic and asymptomatic plaques with 67% sensitivity and 91% speciﬁcity (area under the curve: 0.79;
p ¼ 0.012).
CONCLUSIONS CMR T2 mapping distinguishes different plaque components and accurately quantiﬁes plaque
lipid content noninvasively. Compared with asymptomatic plaques, greater lipid content was found in
symptomatic plaques despite similar degree of luminal stenosis and only modest difference in plaque volumes.
This new technique may ﬁnd a role in determining optimum treatment (e.g., providing an indication for
intensive lipid lowering or by informing decisions of stents vs. surgery). (J Am Coll Cardiol Img 2016;-:-–-)
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TABLE 1 Summary
Asymptomatic Group
Male:female ratio
Age, yrs
CV risks
Hypertension
Hypercholesterolem
Smoking
Diabetes mellitus
Previous CAD/CVA
Medication at time of
Aspirin/antiplatelet
Statins
Beta-blockers
Calcium antagonist
ACE inhibitors/ARB
Anticoagulation
Duplex ultrasound sca
Right:left ratio
Stenosis, %
Values are median (range
ACE ¼ angiotensin-con
artery disease; CEA ¼ ca
cident; NS ¼ not signiﬁca
ABBR EV I A T I ON S
AND ACRONYMS
AHA = American Heart
Association
CMR = cardiovascular magnetic
resonance
DANTE = delay alternating
with nutation for tailored
excitation
IPH = intraplaque hemorrhage
LRNC = lipid-rich necrotic core
MESE = multiecho spin echo
ROC = receiver-operating
characteristic
TOF = time-of-ﬂight
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2L ipid accumulation in the subendothe-lial space, following deposition andretention of apolipoprotein B–con-
taining plasma lipoproteins, is a key process
in the initiation and progression of athero-
sclerosis (1). Studies of ex vivo tissue in coro-
nary (2) and carotid (3) atherosclerosis have
demonstrated that plaques associated with
thrombotic complications tend to contain
larger lipid-rich necrotic core (LRNC), among
other high-risk features such as thin ﬁbrous
cap, inﬁltration of inﬂammatory cells, and
the presence of intraplaque hemorrhage
(IPH). Therefore, 1 of the key goals in risk-
stratifying vulnerable plaques has becomethe identiﬁcation and quantiﬁcation of LRNC using
in vivo vessel wall imaging (4).
Although intensive lipid-lowering therapy can red-
uce total carotid vessel wall area (5), direct evidence of
lipid removal has been sparse (6). One particular
challenge is that evacuated lipids tend to be replaced
by ﬁbrous tissue (7), so that changes in total vessel wall
area might be small or indiscernible by conventional
imaging. As a new generation of lipid-lowering agents
emerges (8,9), tools for robust quantitative assessment
of plaque composition may facilitate reﬁnement and
stratiﬁcation for patient selection, and allow better
monitoring of treatment response.of Patient Characteristics Between Symptomatic and
s
Symptomatic
(n ¼ 15)
Asymptomatic
(n ¼ 11)
Signiﬁcance
(p Value)
2.75:1 2.67:1 NS
73 (49–90) 60 (43–89) 0.046
14 (93.3) 9 (81.8) NS
ia 12 (80.0) 7 (63.6) NS
7 (46.7) 4 (36.4) NS
4 (26.7) 4 (36.4) NS
4 (26.7) 6 (54.5) NS
CEA
s 12 (80.0) 8 (72.7) NS
14 (93.3) 10 (90.9) NS
4 (26.7) 3 (27.3) NS
s 5 (33.3) 3 (27.3) NS
s 6 (40.0) 5 (45.5) NS
3 (20.0) 0 (0) NS
n
6.5:1 1:1.2 0.038
81.3  2.5 84.1  3.0 NS
), n (%), or mean  SEM.
verting enzyme; ARB ¼ angiotensin receptor blocker; CAD ¼ coronary
rotid endarterectomy; CV ¼ cardiovascular; CVA ¼ cerebrovascular ac-
nt.Multicontrast cardiovascular magnetic resonance
(CMR) is an established technique in plaque charac-
terization (10). However, optimal techniques for
quantitative LRNC detection on multicontrast CMR
require injection of contrast media (6,11), and rely on
tissue contrast relative to the adjacent sternocleido-
mastoid muscle, which depends on speciﬁc system
and acquisition parameters. Moreover, multicontrast
CMR suffers from blurring artifacts due to fast spin
echo acquisitions (12) and needs extensive post-
processing to coregister different contrast-weighted
images and correct for image intensity variations (13).
We recently reported a quantitative CMR method
to map T2 relaxation times of plaque components on a
voxel-by-voxel basis (14). Compared to multicontrast
CMR, this novel approach is more objective, as it re-
quires minimal user interaction in the analysis, and
calculates real quantitative information on plaque
composition. This raises the important possibility of
in vivo plaque lipid quantiﬁcation, at high resolution,
across the entire plaque, and without the use of
gadolinium-based contrast. In addition, plaque T2
mapping addresses the need for an absolute physical
parameter that can be standardized among different
CMR systems and widely adopted in multicenter
studies. Accordingly, here we sought: 1) to validate
lipid quantiﬁcation on carotid T2 maps using histol-
ogy gold standard; and 2) to evaluate its potential
clinical application in relation to identifying recently
unstable plaques.
METHODS
STUDY POPULATION. Ethical approval was obtained
from National Research Ethics Services and local R&D
committee. Forty patients awaiting carotid endarter-
ectomy at Oxford University Hospitals NHS Trust
were recruited from November 2011 to June 2014.
Patients were scanned at the Oxford Acute Vascular
Imaging Centre #24 h before surgery. Carotid plaques
were collected at operation. Patients either had
recently symptomatic (median time from index event
2 weeks) or asymptomatic carotid disease, with 50%
to 99% stenosis according to NASCET (North Amer-
ican Symptomatic Carotid Endarterectomy Trial), or
70% to 99% according to ESCT (European Carotid
Surgery Trial) criteria. Plaques were deﬁned as culprit
plaques where they were deemed to have given rise
to either a minor cerebrovascular accident or a tran-
sient ischemic attack as assessed clinically and sup-
ported, where available, by brain magnetic resonance
imaging or computed tomography imaging. Asymp-
tomatic carotid plaques were those that had
no documented clinical symptoms, but with an
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3indication for carotid endarterectomy on the basis of
percent stenosis.
CMR PROTOCOL. Patients were imaged on a Verio
3-T scanner (Siemens Healthcare, Erlangen, Germany)
with a 4-channel phased-array carotid coil (Machnet,
Roden, the Netherlands). Bright-blood time-of-ﬂight
(TOF) angiography of the carotid arteries was ac-
quired to localize carotid bifurcation and lumen ste-
nosis. Two-dimensional carotid T2 maps were
generated from 14 images with echo time of 9 to 127
ms and repetition time of 2,000 ms, acquired using
the multislice delay alternating with nutation for
tailored excitation multiecho spin-echo (DANTE-
MESE) sequence that combined black-blood prepara-
tion on the basis of nonselective DANTE pulse trains
(15) with chemical-shift-selective fat saturated MESE.
DANTE-MESE acquired 10 slices of 2 mm thickness
each, covering 2 cm of the target carotid artery, in
8 min.FIGURE 1 Comparison of T2 Map, Multicontrast CMR, and Histology
T2 mapping identiﬁes different components of an American Heart Assoc
intraplaque hemorrhage (IPH) (yellow/red), and calcium (black). These
ticontrast cardiovascular magnetic resonance (CMR) and are conﬁrmed b
Lipid was further conﬁrmed on Oil Red O staining on adjacent frozen sec
ﬂuorescent nuclear stains; PDW ¼ proton density weighted; T1W ¼ T1 wDATA ANALYSIS. DANTE-MESE image quality was
assessed by an experienced reviewer (L.B.) who
inspected the visibility of the carotid wall boundaries
and rated them from 1 (poor) to 5 (excellent) accord-
ing to standard procedures (16). Patients with overall
quality <3 were excluded from the study.
T2 maps of the carotid arteries were generated voxel
by voxel usingmonoexponential nonlinear ﬁtting (14);
lumen and external vessel boundarieswere segmented
using a validated semiautomated procedure (17). As
reported previously, LRNC without IPH had shorter T2
than normal vessel wall and ﬁbrous tissue, whereas
with recent IPH into the core, T2 was longer than all
other plaque components (14). Therefore, to take into
account the minority of plaques with recent hemor-
rhage into the core, segmentation used dual T2
thresholds, a lower one (T2L) indicating the maximum
T2 value associated with lipid alone and a higher one
(T2H) above which IPH was recorded inside the plaqueiation type VI plaque showing the presence of lipid (blue), recent
plaque components are also visible on different weightings of mul-
y hematoxylin and eosin (H&E) and Masson’s staining on histology.
tion. Asterisk indicates lumen. DAPI ¼ 4’,6-diamidino-2-phenylindole
eighted; T2W ¼ T2 weighted; TOF ¼ time-of-ﬂight.
TABLE 2 Modiﬁed AHA Plaque Type Classiﬁcation by T2 Mapping
(þ TOF) Versus Histology Showed Good Agreement (80.8%)
Histology
CMR (T2 Maps þ TOF)
IV to V VI VII VIII Total
IV to V 7 2 — — 9
VI 1 7 — — 8
VII 1 — 4 1 6
VIII — — — 3 3
Total 9 9 4 4 26
Cohen’s k ¼ 0.73.
AHA ¼ American Heart Association; CMR ¼ cardiovascular magnetic resonance;
TOF ¼ time-of-ﬂight.
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4lipid core. Voxels with T2 values below T2L or above
T2H were thus classiﬁed as LRNC. Signiﬁcant IPH
(T2 > T2H) was deﬁned as >5% of the total cross-
sectional area. We also reported LRNC values on the
basis of T2L alone, taking no account of hemorrhage.
To use the data most efﬁciently, segmentation
performance was estimated by leave-1-outFIGURE 2 Quantiﬁcation of Plaque Lipid
T2 and segmented map of (A) a plaque with large lipid-rich necrotic cor
their matching histology. LRNC was segmented from the T2 map by thre
3-dimensional representations of plaque lipid distribution. Stacks of slices
(for illustration). H&E ¼ hematoxylin and eosin.cross-validation. Lipid area (%) was computed for all
possible combinations of T2L (range 30 to 50 ms) and
T2H (range 70 to 120 ms) to ﬁnd the pair of threshold
values that achieved the optimal lipid segmentation
on T2 maps (i.e., the highest Pearson correlation co-
efﬁcient R against lipid quantiﬁcation on histology).
All algorithms were implemented in Matlab (Math-
Works, Natick, Massachusetts). Plaque type was
also classiﬁed on the basis of T2 mapping and TOF
data (for identiﬁcation of IPH and calcium) using
the modiﬁed American Heart Association (AHA)
scheme (10).
HISTOLOGY. Carotid plaques were collected at end-
arterectomy and divided into 2 halves at the point of
maximal stenosis: one half was snap-frozen and the
other half processed for parafﬁn embedding. Parafﬁn
sections (5 mm) were obtained at 1-mm intervals for
histological examination using hematoxylin and
eosin (Sigma-Aldrich, Poole, United Kingdom) and
Masson’s trichrome (Merck-Millipore, Nottingham,
United Kingdom), which identiﬁed collagen in thee (LRNC) and (B) a plaque with multiple smaller lipid-rich pools, and
sholding (voxels with T2 <42 ms or T2 >90 ms). Right panels show
show lumen (red) and lipid (blue contours) segmented from T2 maps
FIGURE 3 Correlation of Lipid Area Between T2 Mapping and Histology
80
60
40
20
0
-20
20 40 60 80
Lipid Area (%) on T2 Map
Li
pi
d 
Ar
ea
 (%
)
o
n
 H
is
to
lo
gy
60 matched slices
R = 0.85, P < 0.001 ***
20
0
-20
80
+2SD = +20.1%
Bias = +0.03%
-2SD = -20.1%
Average T2 Map & Histology Lipid Area (%)
H
is
to
lo
gy
 - 
T2
 M
ap
Li
pi
d 
Ar
ea
 (%
)
20 40 60
A
B
(A) Scatter plot of lipid area (%) by slice location showed excellent correlation (R ¼ 0.85,
p < 0.001). (B) Bland-Altman analysis showed good agreement between histology and T2
map with minimal bias.
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5ﬁbrous tissue (green), as well as ﬁbrin and erythro-
cytes from IPH (bright red). Lipid area without pre-
vious IPH appeared transparent or unstained in both
hematoxylin and eosin and Masson’s trichrome stain.
Stained slides were scanned using the NanoZoomer
(Hamamatsu Photonics, Hamamatsu City, Japan) vir-
tual pathology system. Frozen sections (20 mm) at the
mirror plane of division on 20 randomly selected
plaques were obtained for Oil Red O (Sigma-Aldrich)
staining to conﬁrm lipid presence. Because IPH
occurred exclusively inside, and as part of, the LRNC,
the boundary of IPH against LRNC was often impos-
sible to deﬁne on histology (Online Figure 1). The
total histological lipid area (%) was hence calculated
by combining lipid area with and without IPH. Total
vessel cross-sectional area and lipid area (%) were
obtained by manual segmentation using ImageJ,
64-bit, version 1.46r (National Institutes of Health,
Bethesda, Maryland), as previously described (18).
Plaque type was classiﬁed histologically using the
AHA scheme (10).
LOCATION MATCHING. One investigator (L.B.) blin-
ded to histology measured the distance from carotid
bifurcation of T2 map locations and provided the
corresponding T1-weighted images to a second
investigator (J.T.C.) who obtained histology on the
basis of the speciﬁc distance from bifurcation, and
ﬁne-tuned the exact matching location using local
vessel morphology from the T1-weighted images
provided.
SCAN-RESCAN REPRODUCIBILITY. Scan-rescan repro-
ducibility of lipid quantiﬁcation by T2 mapping was
studied in 10 additional patients recruited on an un-
selected sequential basis. They were taken out of the
scanner after the ﬁrst scan and left sitting for 2 min
before the second scan. Both scans acquired 10
contiguous slices to cover the entire plaque and
assess the reproducibility of lipid area (%) per plaque.
STATISTICAL ANALYSIS. All statistical analyses are
reported as mean  SEM, unless otherwise stated;
Student t tests and chi-square tests were performed.
Lipid area correlation was calculated using both
slice locations and plaques as the unit of analysis.
Leave-1-out cross-validation was performed on the
slice-by-slice dataset of independent lipid area
measurements from T2 maps and histology.
RESULTS
PATIENT CHARACTERISTICS. CMR scan quality $3
was achieved for 26 of 40 plaques, 15 symptomatic
and 11 asymptomatic. Patient characteristics are
summarized in Table 1. There was no signiﬁcantdifference between genders, major cardiovascular
risk factors or medications on admission between
groups.
AHA CLASSIFICATION. Figure 1 shows how different
plaque components can be identiﬁed on T2 maps. To
evaluate how accurately T2 mapping can determine
plaque types, we used the modiﬁed AHA plaque
classiﬁcation system and compared this directly
against histological classiﬁcation. Table 2 shows
plaque types determined by T2 map (þ TOF) against
histology, which showed good agreement (80.8%)
between the 2 methods (Cohen’s k ¼ 0.73).
LIPID QUANTIFICATION. We next used T2 maps to
quantify plaque lipid content (Figure 2). Varying
according to the length of each carotid atherosclerotic
lesion, an average of 2.3 slices of T2 map data were
obtained per plaque, yielding 60 matched slices.
Using leave-1-out cross-validation, the combination
T2L ¼ 42 ms and T2H ¼ 90 ms produced maximum
R ¼ 0.85 (p < 0.001) against lipid area (%) measured
FIGURE 4 Plaque-
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6on histology (Figure 3A), thus achieving optimal T2
map segmentation for lipid quantiﬁcation. Addition-
ally, root mean square error was minimum (10.5%)
and Bland-Altman analysis conﬁrmed a high degree
of agreement between T2 maps and histology, with
only 0.03% underestimation on T2 maps (Figure 3B).
For technical validation, we made multiple com-
parisons of T2 maps and tissue stains per slice. How-
ever, for biological applications, the unit of analysis
would be per plaque rather than per slice. Grouping
individual slice locations from each plaque on the
same scatter plot, we showed that data points from
the same plaque were relatively closely clustered
together (Figure 4A), indicating that slices from the
same plaque tend to contain similar proportions of
lipid. Furthermore, comparing the average lipid area
(%) per plaque measured by T2 map and by histology
maintained a strong correlation (R ¼ 0.83, p < 0.001)
(Figure 4B).by-Plaque Correlation of Lipid Area
20 40 60 80
Lipid Area (%) on T2 Map
R = 0.83, P < 0.001***
26 plaques
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contain similar proportions of lipid. (B) Strong correlation maintained
ue comparison (R ¼ 0.83, p < 0.001).SYMPTOMATIC VERSUS ASYMPTOMATIC. We then
tested using T2 mapping whether LRNC size varied
between different clinical presentations. Symptom-
atic plaques were found to have signiﬁcantly higher
lipid area (%), compared to asymptomatic plaques
(31.5  3.7% vs. 15.8  3.1%; p ¼ 0.005, relative dif-
ference 99.4%) (Figure 5A). This was despite similar
degree of carotid stenosis (81.3  2.5% symptomatic
vs. 84.1  3.0% asymptomatic; p ¼ NS), and only
a modest difference in terms of plaque volume
(128.0  6.0 mm3 symptomatic vs. 105.6  9.4 mm3
asymptomatic; p ¼ 0.04; relative difference ¼ 21.2%).
In addition, using an established deﬁnition of large
LRNC as $25% of cross-sectional area (3,19), we
further conﬁrmed that symptomatic plaques had
signiﬁcantly larger LRNC using T2 mapping alone (p ¼
0.003) (Figure 5B). Finally, the receiver-operating
characteristic (ROC) area under the curve was 0.79
(p ¼ 0.01), indicating that lipid quantiﬁcation by T2
mapping has a good ability to discriminate between
symptomatic and asymptomatic plaques in our clin-
ical cohorts. ROC analysis determined the optimal
cutoff for LRNC between clinical cohorts to be w25%
(sensitivity ¼ 67%, speciﬁcity ¼ 91%) (Figure 5C).
INTRAPLAQUE HEMORRHAGE. To clarify whether
the inclusion of IPH in our calculation with a second
T2 threshold had inﬂuenced our results, we examined
the prevalence of IPH and its contribution to the total
lipid area (%). Sixteen of the total 60 slices contained
signiﬁcant (>5%) IPH. Of these, only 7 had IPH inﬁl-
trating >50% of the lipid core. Thus IPH made a
relatively minor contribution to the total lipid mea-
surement. Figure 6 shows the copresence of IPH and
lipid-ﬁlled macrophage foam cells. We then rean-
alyzed our data using a single T2 threshold of <42 ms
for segmentation and lipid area calculation, by so
doing effectively excluded IPH (long T2) as part of the
LRNC in T2 map segmentation, yet the strength of
correlation was similar to our dual T2 threshold
approach (R ¼ 0.79 vs. 0.85). In fact, if we excluded
those 7 slices with large (>50%) IPH from the cohort,
the correlation of the remaining 53 slices using
a single threshold (<42 ms) approach went back to
R ¼ 0.85.
SCAN-RESCAN REPRODUCIBILITY. One of the 10
carotid plaques scanned to evaluate reproducibility
was rejected due to low image quality during rescan.
For the remaining 9 plaques, lipid core measurements
ranged from 5.7% to 36.6% with a mean of 20.3%. The
scan-rescan reproducibility was excellent (intraclass
correlation coefﬁcient ¼ 0.89; 95% conﬁdence inter-
val: 0.59 to 0.98; coefﬁcient of variation ¼ 8.9%
[plaque-by-plaque comparison]).
FIGURE 5 Symptomatic Plaques Contain More Lipid Than Asymptomatic Plaques
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(A) Symptomatic plaques contained signiﬁcant more lipid than asymptomatic plaques (31.5  3.7% vs. 15.8  3.1%; p ¼ 0.005) despite similar
degree of luminal stenosis. (B) Chi-square test using an established cutoff of >25% to deﬁne a large lipid-rich necrotic core (LRNC)
showed similar results. (C) Receiver-operating characteristic curve analysis showed that T2 mapping has a fair to good ability to
discriminate between symptomatic and asymptomatic plaques. *p < 0.05, **p < 0.01. AUC ¼ area under the curve.
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7DISCUSSION
This work makes 2 principal ﬁndings. First, in vivo T2
mapping, on a voxel-by-voxel basis, and at high res-
olution, enables accurate and highly reproducible
quantiﬁcation of plaque lipid, validated with histol-
ogy. Second, lipid quantiﬁcation by T2 mapping can
distinguish recently symptomatic plaques with high
sensitivity and speciﬁcity.
Deposition and retention of cholesterol-rich lipo-
proteins is a cardinal feature of atherosclerosis,
occurring from the earliest foam cell lesions through
to the complex plaques of advanced disease. Where
the rate of deposition exceeds the rate of clearance,
cholesterol and cholesterol derivatives can accumu-
late within the plaque. The presence of a large LRNC
(especially associated with a thin overlying ﬁbrous
cap) has been associated with high risk of rupture and
atherothrombotic complications (3). Furthermore, the
presence of lipid in the plaque is a driver of local
inﬂammation (20) and altered gene expression (21).Because of these central roles, quantiﬁcation of pla-
que lipid has been a key aim of various atheroscle-
rosis imaging techniques such as intravascular
ultrasound (22), near infrared spectroscopy (23), car-
diac computed tomography (24), and vascular mag-
netic resonance imaging (11).
Since the ﬁrst description of Toussaint et al. (25),
magnetic resonance techniques have been applied for
the detection of LRNC (26,27). However, a signiﬁcant
limitation of this approach is low sensitivity, such
that LRNC can be detected only in a minority of pla-
ques with relatively large coalesced lipid pools. In a
survey of 100 patients with varying extents of coro-
nary atheroma, only 20% had a discernable LRNC in
the carotid artery on multicontrast CMR (28). Reliable
detection of small scattered pools of lipid depends
on image resolution and signal-to-noise ratio in both
T2 mapping and multicontrast CMR. The main
advantage of T2 mapping is to provide quantitative
information, on a per-voxel basis, using direct mea-
surement of an absolute physical property of plaque
FIGURE 6 IPH Is Structurally Integral to the LRNC
(A) Large intraplaque hemorrhage (IPH) in background lipid-rich necrotic core (LRNC). Erythrocytes and ﬁbrin staining on Masson’s
trichrome conﬁrmed IPH. Copresence of macrophage and lipid droplets conﬁrmed by immunohistochemistry against cluster of differentiation
68 (CD68) and adipophilin (35). (B) Small IPH areas, structurally continuous with background LRNC, detected by T2 mapping and histology.
Note: a small area of fresh blood at the specimen border seen at 12 o’clock position is a surgical artifact. H&E ¼ hematoxylin and eosin.
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8components. Our approach to lipid quantiﬁcation is
therefore more objective and less dependent on
acquisition parameters than multicontrast CMR,
which relies on relative signal intensities for plaque
segmentation. In addition, T2 mapping does not suf-
fer from blurring artifacts intrinsic to fast spin echo
acquisition (12), nor does it require image coregistra-
tion and intensity correction (13). Finally, it is more
time efﬁcient (one-ﬁfth of the time required by mul-
ticontrast protocol for LRNC quantiﬁcation) (6,11) and
without exposing patients to a gadolinium-based
contrast agent. Because the validation required tis-
sue obtained by endarterectomy (undertaken for se-
vere stenotic disease), our series contains relatively
large lesions (of AHA classes IV to VIII on histology).
In this context, plaque lipid was detectable in virtu-
ally all cases.
Atherosclerosis regression is a term used to denote
favorable remodeling of plaque, for instance in
response to aggressive reduction in plasma level ofatherogenic lipoproteins (29). Normalization of plasma
lipid proﬁle in genetically modiﬁed hyperlipidemic
mice with atherosclerosis leads to marked loss of pla-
que lipid and deposition of ﬁbrous tissue (7), with
similar changes inferred in man (30). This has impor-
tant implications in the clinic because some anti-
atherosclerotic agents may well change plaque lipid
content, without necessarily altering total plaque
volume. This suggests that accurate quantiﬁcation of
plaque lipid might prove useful for patient stratiﬁca-
tion and selection for intensive lipid lowering thera-
pies or monitoring of response to treatment, including
in clinical trials. The technique validated here shows
excellent scan-rescan reproducibility and would be
well suited to serial application in lipid-intervention
trials. This may be important since several new clas-
ses of lipid lowering therapies have been developed,
including lipoprotein(a) and apolipoprotein B anti-
sense, microsomal triglyceride transfer protein inhi-
bition, cholesteryl ester transfer protein inhibitors,
PERSPECTIVES
COMPETENCY IN MEDICAL KNOWLEDGE: Quantitative T2
mapping is a novel technique in characterization of carotid
atherosclerotic plaques. Using histological validation, this study
demonstrated its ability to differentiate various plaque compo-
nents, with an emphasis on lipid quantiﬁcation. Symptom-related
plaques were shown to contain signiﬁcantly more lipid despite
similar degree of luminal stenosis and only modest difference in
plaque volume compared with asymptomatic plaques. T2 map-
ping is accurate and reproducible; it is an alternative technique to
the conventional multicontrast approach, which may be of value
in future lipid intervention trials and cardiovascular risk
stratiﬁcation.
TRANSLATIONAL OUTLOOK: Technical improvements are
actively pursued, to reduce imaging time by compressed sensing,
increase spatial resolution coverage and signal-to-noise ratios by
better multichannel coils, and reduce motion artifacts by the
development of image navigator–based approaches. How the
changes in the size of lipid-rich core in vulnerable plaques, as an
imaging biomarker, translate to the modiﬁcation of cardiovas-
cular risks remain to be elucidated.
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9and proprotein convertase subtilisin/kexin type 9 in-
hibitors, but considerations of cost effectiveness,
mode of administration, and, in some cases, potential
toxicity mean that they are unlikely to be used indis-
criminately in patients with atherosclerotic disease.
Methods for rational stratiﬁcation are therefore
needed.
Applying T2 mapping in our different clinical co-
horts, we found that despite having similar degree of
carotid stenosis, and only a modest 21.2% difference
in terms of plaque volume, symptomatic plaques had
99.4% larger LRNC than asymptomatic plaques. ROC
analysis conﬁrmed our technique having good ability
to distinguish between symptomatic and asymptom-
atic plaques with optimal LRNC cutoff at 25% of the
cross-sectional area, in agreement with large-scale
histological series in both carotid (3) and coronary
(31) locations. The ability to accurately quantify pla-
que lipid might also prove useful in informing de-
cisions between carotid surgery and stenting because
a large LRNC is considered to be an important factor
determining the amount of stent-related downstream
debris (32) and has been shown to increase risk of
stroke following carotid stenting (32,33). Three-
dimensional rendering of lipid distribution in rela-
tion to local vessel anatomy using quantitative T2
mapping data may assist interventional procedural
planning to minimize such risks (Figure 2, right
panels).
STUDY LIMITATIONS. The main limitation of our
method is the sensitivity to motion artifacts, a fact re-
ﬂected in the scan rejection rate (35%), which is com-
parable to that of multicontrast CMR (30%) (11).
Strategies for motion correction are currently being
actively pursued. Another limitation is the challenge to
measure IPH independently, mainly because of the
tendency for hemorrhage to be mixed with LRNC.
Moreover, as IPH ages and organizes, not only do its
magnetic resonance properties change (16), but also its
histological appearance, as organization replaces
ﬁbrin with a more collagen-like extracellular matrix
structure (34). We therefore analyzed our data using 2
approaches: 1 with dual T2 thresholds that included
both lipid and IPH and another with a single T2
threshold to effectively exclude IPH as part of the
LRNC measurement. By either method, the strength
of correlation was similar (R ¼ 0.79 vs. 0.85). This
demonstrated empirically that T2 mapping does track
plaque lipid content accurately, whether or not IPH is
considered as part of the LRNC calculation. Finally,
this histological validation study has a relatively
small number of subjects and CMR slices. To utilize
the available data most efﬁciently, we employedleave-1-out cross-validation to test the performance of
our T2 segmentation model on data that were not used
to build it.
CONCLUSIONS
In conclusion, we provided histological validation of
a new in vivo multislice T2 mapping technique for
quantiﬁcation of plaque lipid content. Not only can
T2 mapping distinguish between symptomatic and
asymptomatic plaques on the basis of their lipid
content, but we showed that despite similar degree
of luminal stenosis and only modest difference in
plaque volume, symptomatic plaques contained
nearly double the lipid content compared with
asymptomatic plaques on T2 maps. This technique
may be of value in patient selection and evaluating
response to new antiatherosclerotic treatment and
interventions.
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